Imagion Biosystems is now a publicly traded company after completing a heavily supported A$12 million initial public offering (IPO) on the Australian Securities Exchange. Imagion issued 60 million new shares as part of the IPO at A$0.20 per share, valuing the company at A$43 million upon listing.
The company’s shares trade under the symbol IBX on the Australian Securities Exchange. Download the official announcement.
Quarterly Activity Report – Quarter ending 31 December 2023
January 31, 2024
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal